Rasna Therapeutics, Inc. (RASP)
USD 0.0
(900.0%)
USD 0.0
(900.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.05 Million USD | 15.65% |
| 2022 | 1.77 Million USD | -34.48% |
| 2021 | 2.7 Million USD | -0.01% |
| 2020 | 2.7 Million USD | 12.42% |
| 2019 | 2.4 Million USD | 13.63% |
| 2018 | 2.11 Million USD | 38.72% |
| 2017 | 1.52 Million USD | 2005.47% |
| 2016 | 72.57 Thousand USD | 534.55% |
| 2015 | 11.43 Thousand USD | 1067.04% |
| 2014 | 980.00 USD | 61.98% |
| 2013 | 605.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 2.23 Million USD | 4.73% |
| 2024 Q1 | 2.12 Million USD | 3.81% |
| 2023 Q2 | 1.92 Million USD | 2.8% |
| 2023 FY | 2.05 Million USD | 15.65% |
| 2023 Q1 | 1.87 Million USD | 5.43% |
| 2023 Q4 | 2.05 Million USD | 1.94% |
| 2023 Q3 | 2.01 Million USD | 4.68% |
| 2022 Q1 | 2.53 Million USD | -6.28% |
| 2022 FY | 1.77 Million USD | -34.48% |
| 2022 Q4 | 1.77 Million USD | -4.51% |
| 2022 Q3 | 1.85 Million USD | -14.54% |
| 2022 Q2 | 2.17 Million USD | -14.34% |
| 2021 Q1 | 2.83 Million USD | 4.58% |
| 2021 FY | 2.7 Million USD | -0.01% |
| 2021 Q3 | 3.01 Million USD | 4.13% |
| 2021 Q2 | 2.89 Million USD | 2.3% |
| 2021 Q4 | 2.7 Million USD | -10.24% |
| 2020 Q1 | 2.48 Million USD | 3.11% |
| 2020 Q4 | 2.7 Million USD | 3.06% |
| 2020 FY | 2.7 Million USD | 12.42% |
| 2020 Q3 | 2.62 Million USD | -1.43% |
| 2020 Q2 | 2.66 Million USD | 7.33% |
| 2019 Q2 | 2.37 Million USD | 2.02% |
| 2019 Q1 | 2.33 Million USD | 9.98% |
| 2019 Q3 | 2.46 Million USD | 3.71% |
| 2019 Q4 | 2.4 Million USD | -2.35% |
| 2019 FY | 2.4 Million USD | 13.63% |
| 2018 FY | 2.11 Million USD | 38.72% |
| 2018 Q4 | 2.11 Million USD | 22.06% |
| 2018 Q3 | 1.73 Million USD | 23.02% |
| 2018 Q2 | 1.41 Million USD | 7.0% |
| 2018 Q1 | 1.31 Million USD | -13.72% |
| 2017 Q4 | 1.52 Million USD | -6.49% |
| 2017 Q1 | 4.2 Million USD | 394.21% |
| 2017 Q2 | 1.52 Million USD | -63.62% |
| 2017 Q3 | 1.63 Million USD | 7.0% |
| 2017 FY | 1.52 Million USD | 2005.47% |
| 2016 Q4 | 849.85 Thousand USD | 1071.03% |
| 2016 Q2 | 18.56 Thousand USD | 10.88% |
| 2016 Q1 | 16.74 Thousand USD | 18.65% |
| 2016 Q3 | 72.57 Thousand USD | 290.93% |
| 2016 FY | 72.57 Thousand USD | 534.55% |
| 2015 Q4 | 14.11 Thousand USD | 23.37% |
| 2015 Q2 | 10.02 Thousand USD | 284.95% |
| 2015 FY | 11.43 Thousand USD | 1067.04% |
| 2015 Q3 | 11.43 Thousand USD | 14.05% |
| 2015 Q1 | 2605.00 USD | 67.52% |
| 2014 Q4 | 1555.00 USD | 58.67% |
| 2014 Q2 | 605.00 USD | -51.79% |
| 2014 Q1 | 1255.00 USD | 0.0% |
| 2014 FY | 980.00 USD | 61.98% |
| 2014 Q3 | 980.00 USD | 61.98% |
| 2013 FY | 605.00 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -7378.457% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 78.327% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 97.169% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -153.657% |
| Rebus Holdings, Inc. | 5.24 Million USD | 60.863% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.524% |
| Qrons Inc. | 1.48 Million USD | -37.808% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -67.309% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.262% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4490.042% |
| Skye Bioscience, Inc. | 14.07 Million USD | 85.421% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 96.151% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 78.589% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -386.651% |
| SQZ Biotechnologies Company | 50.03 Million USD | 95.9% |
| Intellipharmaceutics International Inc. | 12 Million USD | 82.916% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 46.732% |
| Mesoblast Limited | 188.44 Million USD | 98.911% |
| Marizyme, Inc. | 26.67 Million USD | 92.309% |
| Genus plc | 485 Million USD | 99.577% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 64.886% |
| Pharming Group N.V. | 244.07 Million USD | 99.159% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -2.061% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 18.47% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 46.011% |
| ContraFect Corporation | 32.53 Million USD | 93.694% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -3.546% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 46.401% |
| IMV Inc. | 37.93 Million USD | 94.592% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 82.582% |
| MultiCell Technologies, Inc. | 1617.67 USD | -126722.22% |
| ONE Bio Corp. | 27.49 Million USD | 92.539% |
| Accustem Sciences Inc. | 1.07 Million USD | -90.094% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.35% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | 3.002% |
| Q BioMed Inc. | 8.13 Million USD | 74.775% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.526% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 60.133% |
| Biomind Labs Inc. | 1.49 Million USD | -36.898% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.272% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 77.311% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 88.852% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -43.08% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1343.798% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -920.09% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 64.295% |
| GB Sciences, Inc. | 5.41 Million USD | 62.131% |
| Alpha Cognition Inc. | 7.16 Million USD | 71.366% |
| HST Global, Inc. | 593.59 Thousand USD | -245.618% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -62.927% |
| Halberd Corporation | 728.71 Thousand USD | -181.53% |
| Enzolytics Inc. | 365.26 Million USD | 99.438% |
| Agentix Corp. | 2.51 Million USD | 18.282% |
| Resverlogix Corp. | 67.39 Million USD | 96.956% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -144.603% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.539% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -19.695% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 91.71% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 82.764% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 44.025% |
| AVAX Technologies, Inc. | 3.99 Million USD | 48.631% |
| Zenith Capital Corp. | 27.56 Thousand USD | -7341.565% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.845% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -759.64% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 45.062% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -201.331% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 24.342% |
| Kadimastem Ltd | 3.5 Million USD | 41.465% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -2965.286% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 95.918% |
| BioStem Technologies, Inc. | 15.9 Million USD | 87.101% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -341.483% |
| LadRx Corporation | 2.2 Million USD | 6.769% |
| Cell Source, Inc. | 15.8 Million USD | 87.021% |
| Regen BioPharma, Inc. | 5.45 Million USD | 62.409% |
| Regen BioPharma, Inc. | 5.45 Million USD | 62.409% |
| NovAccess Global Inc. | 7.86 Million USD | 73.901% |
| Affymax, Inc. | 8.87 Million USD | 76.873% |
| Itoco Inc. | 1.65 Million USD | -24.1% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 66.084% |
| Mobile Lads Corp. | 1.31 Million USD | -56.191% |
| CytoDyn Inc. | 127.89 Million USD | 98.396% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -4808.168% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -30.975% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 81.426% |
| SYBLEU INC | 681.41 Thousand USD | -201.075% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 66.378% |
| International Stem Cell Corporation | 5.27 Million USD | 61.123% |
| Bioxytran, Inc. | 3.24 Million USD | 36.865% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -227.826% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 55.566% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 94.996% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 90.786% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1.292% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 62.549% |
| Neutra Corp. | 973.52 Thousand USD | -110.735% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 92.929% |
| PureTech Health plc | 125.58 Million USD | 98.366% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 45.395% |
| IXICO plc | 1.9 Million USD | -7.961% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 90.007% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.014% |
| CSL Limited | 18.62 Billion USD | 99.989% |
| Cellectis S.A. | 249.36 Million USD | 99.177% |